Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/01/2026 ,inter alia, to consider and approve Pursuant to Regulation 30 of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kabra Drugs Ltd has informed BSE that its Board will meet on 1 January 2026 to consider several major strategic items. The Board will evaluate a proposal to change the company's name to reflect a new business direction. It will also consider acquiring four target companies across pharmaceutical formulations, medical equipment manufacturing, electric vehicle (EV) manufacturing, and steel/tin sheets. Additionally, the Board plans to alter the Main Objects clause of the Memorandum of Association to allow diversification into EV manufacturing, steel/tin sheets trading, and solar energy equipment manufacturing and power generation. Shareholder and MCA approvals will be required for the name change and MOA amendment.
This signals a significant pivot away from the company's existing pharma-focused business into unrelated high-growth sectors like EVs, steel, and solar energy. Shareholders should watch the 1 January outcome closely, as approved acquisitions and a name change could materially alter the company's risk profile, valuation, and future earnings mix.